세계의 부신암 진단 시장 보고서(2025년)
Adrenal Cancer Diagnostics Global Market Report 2025
상품코드 : 1824563
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,666,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,635,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,605,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

부신암 진단 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 6.5%를 나타내 1,908억 달러로 성장할 전망입니다. 예측 기간의 성장은 맞춤형 의료 접근법, 침습 수술 증가, 원격 의료 및 원격 진찰, 액체 생검 개발, 유전 상담 서비스 확대 등에 기인합니다. 예측 기간의 주요 동향으로는 진단 혁신에 대한 규제 지원, 디지털 퍼솔로지의 채용, 영상 기술의 진보, 리퀴드 바이옵시의 개발, 정밀의료를 위한 유전체 프로파일링 등이 있습니다.

향후 5년간의 성장률 6.5%라고 하는 예측은 전회의 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역 마찰은 한국과 네덜란드에서 개발된 리퀴드 바이옵시 패널과 PET-CT 방사성 의약품의 가격을 상승시켜 종양 프로파일링 지연과 병리 부문의 비용 상승을 초래하여 미국의 암 진단에 지장을 초래할 가능성이 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 보다 광범위하게 이어질 수 있습니다.

예상되는 담배 흡연 증가는 부신암 진단 시장 성장을 가속합니다. 담배의 흡연은 정신작용이 있는 중독성 알칼로이드인 니코틴을 포함한 담배 연소가스를 빨아들이거나 토합니다. 부신선종과 부신피질암을 포함한 부신암은 담배 흡연과 관련된 위험 증가와 관련이 있습니다. 담배연기에 포함된 발암물질이 부신세포의 DNA 손상을 일으켜 암의 원인이 되는 돌연변이를 일으킬 가능성이 있습니다. 주목할 점은 캐나다 통계국의 보고에 따르면 2022년 7월의 담배 생산량은 2021년 6월에 비해 5.8% 증가했으며, 2022년 6월 총 판매 횟수는 14억개에 달했다는 점입니다. 이처럼 담배의 흡연율 증가는 부신암 진단 시장의 중요한 촉진요인입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

KTH
영문 목차

영문목차

Adrenal cancer diagnostics involve the identification and detection of cancer originating in the adrenal glands, situated above the kidneys. This process encompasses a series of medical assessments, tests, and procedures designed to establish the presence of adrenal cancer, playing a crucial role in effective treatment planning and management.

The primary diagnostic tests for adrenal cancer include magnetic resonance imaging (MRI), computed tomography (CT) scans, X-rays, positron emission tomography (PET) scans, and biopsies. Magnetic resonance imaging (MRI) is a medical imaging technique that utilizes strong magnetic fields and radio waves to generate detailed and high-resolution images of the body's internal structures. Treatment modalities encompass surgery, chemotherapy, radiotherapy, targeted cancer therapies, and others tailored for pheochromocytoma, adrenal cortical carcinoma, and various tumor types. These treatments are administered by diverse end-users such as hospitals, ambulatory surgical centers, cancer centers, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The adrenal cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides adrenal cancer diagnostics market statistics, including adrenal cancer diagnostics industry global market size, regional shares, competitors with an adrenal cancer diagnostics market share, detailed adrenal cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the adrenal cancer diagnostics industry. This adrenal cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adrenal cancer diagnostics market size has grown strongly in recent years. It will grow from $140.35 billion in 2024 to $148.54 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increased incidence and awareness, genetic and molecular testing advances, biopsy techniques improvement, enhanced endocrine testing, integration of artificial intelligence (AI).

The adrenal cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $190.8 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to personalized medicine approaches, rise in minimally invasive procedures, telemedicine and remote consultations, liquid biopsy development, expanded genetic counseling services. Major trends in the forecast period include regulatory support for diagnostic innovations, digital pathology adoption, advancements in imaging technologies, liquid biopsy development, genomic profiling for precision medicine.

The forecast of 6.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. oncology diagnostics by inflating prices of liquid biopsy panels and PET-CT radiopharmaceuticals developed in South Korea and the Netherlands, resulting in delayed tumor profiling and higher pathology department costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated rise in cigarette smoking is poised to drive the growth of the adrenal cancer diagnostics market. Cigarette smoking involves inhaling and exhaling fumes from burning tobacco containing nicotine, an addictive alkaloid with psychoactive effects. Adrenal cancer, including adenomas and adrenocortical carcinomas, has been linked to increased risks associated with cigarette smoking. The carcinogens in tobacco smoke can lead to DNA damage in adrenal cells, resulting in mutations that may cause cancer. Notably, Statistics Canada reported a 5.8% increase in cigarette production in July 2022 compared to June 2021, with the total number of cigarettes sold reaching 1.4 billion in June 2022. Thus, the growing prevalence of cigarette smoking is a key driver for the adrenal cancer diagnostics market.

Government initiatives supporting cancer are expected to propel the growth of the adrenal cancer diagnostics market. These initiatives involve significant actions taken by governments to address challenges, improve diagnostic services' quality and accessibility, and support research for effective adrenal cancer diagnostics. In April 2023, the Biden-Harris administration, as per the National Institutes of Health (NIH), established an initiative to reduce cancer-related deaths by 50% within 25 years while enhancing support for individuals enduring and surviving cancer. Government initiatives contribute significantly to driving the growth of the adrenal cancer diagnostics market.

Leading companies in the adrenal cancer diagnostics market are launching innovative initiatives through advanced collaboration models, such as the CancerX Startup Accelerator, to boost digital innovations in cancer care. This Accelerator is designed to offer promising startups mentorship, training, and direct connections to key stakeholders in the healthcare sector, including providers and pharmaceutical firms. For instance, in November 2023, CanceRx, LLC, a US-based public-private partnership aimed at enhancing innovation in the fight against cancer, announced the launch of this initiative during the Future of Cancer Care Summit held in Tampa, Florida. The program plans to select its first cohort of about 15 to 20 companies starting in March 2024, concentrating on critical themes such as clinical research, screening, diagnosis, and treatment. It is anticipated that this initiative will significantly advance the objectives of the Cancer Moonshot initiative by tackling unmet needs in cancer care and promoting the development of effective digital health tools in oncology.

In June 2023, Quest Diagnostics, a US-based medical laboratory company, acquired Haystack Oncology, Inc. for an undisclosed sum. As a result of this acquisition, Quest Diagnostics will integrate Haystack Oncology's minimal residual disease (MRD) testing technology, which is based on circulating tumor DNA (ctDNA). Haystack Oncology, Inc. is a biotechnology company located in the United States.

Major companies operating in the adrenal cancer diagnostics market report are Johnson And Johnson Pvt Ltd., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, GSK PLC, AstraZeneca PLC, Abbott Laboratories, Siemens Healthcare GmbH, Becton Dickinson and Company, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Agilent Technologies, Hologic Inc., PerkinElmer Inc., Illumina Inc., Roche Diagnostics, BioMerieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., Bruker Corporation, Exact Sciences Corp., Natera Inc., Invitae Corporation, Qiagen NV, Guardant Health Inc., Foundation Medicine Inc., NanoString Technologies Inc., TRS Technologies Inc., Morgan Advanced Materials, APC International Ltd., Annon Piezo Technology Co. Limited

North America was the largest region in the adrenal cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adrenal cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the adrenal cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The adrenal cancer diagnostics market consists of revenues earned by entities by providing genetic testing, histopathology, blood tests, and dexamethasone suppression tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The adrenal cancer diagnostics market also includes sales of ultrasound machines, reagents and test kits, microscopes, histology kits, and microtomes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adrenal Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adrenal cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for adrenal cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The adrenal cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Adrenal Cancer Diagnostics Market Characteristics

3. Adrenal Cancer Diagnostics Market Trends And Strategies

4. Adrenal Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Adrenal Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

6. Adrenal Cancer Diagnostics Market Segmentation

7. Adrenal Cancer Diagnostics Market Regional And Country Analysis

8. Asia-Pacific Adrenal Cancer Diagnostics Market

9. China Adrenal Cancer Diagnostics Market

10. India Adrenal Cancer Diagnostics Market

11. Japan Adrenal Cancer Diagnostics Market

12. Australia Adrenal Cancer Diagnostics Market

13. Indonesia Adrenal Cancer Diagnostics Market

14. South Korea Adrenal Cancer Diagnostics Market

15. Western Europe Adrenal Cancer Diagnostics Market

16. UK Adrenal Cancer Diagnostics Market

17. Germany Adrenal Cancer Diagnostics Market

18. France Adrenal Cancer Diagnostics Market

19. Italy Adrenal Cancer Diagnostics Market

20. Spain Adrenal Cancer Diagnostics Market

21. Eastern Europe Adrenal Cancer Diagnostics Market

22. Russia Adrenal Cancer Diagnostics Market

23. North America Adrenal Cancer Diagnostics Market

24. USA Adrenal Cancer Diagnostics Market

25. Canada Adrenal Cancer Diagnostics Market

26. South America Adrenal Cancer Diagnostics Market

27. Brazil Adrenal Cancer Diagnostics Market

28. Middle East Adrenal Cancer Diagnostics Market

29. Africa Adrenal Cancer Diagnostics Market

30. Adrenal Cancer Diagnostics Market Competitive Landscape And Company Profiles

31. Adrenal Cancer Diagnostics Market Other Major And Innovative Companies

32. Global Adrenal Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Adrenal Cancer Diagnostics Market

34. Recent Developments In The Adrenal Cancer Diagnostics Market

35. Adrenal Cancer Diagnostics Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기